About this item:

729 Views | 835 Downloads

Author Notes:

Address correspondence to: Srdan Verstovsek, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine, 1515 Holcombe Blvd, Unit 418, Houston, TX 77030, USA, Tel: (713) 745-3429, Fax: (713) 794-4297, sverstov@mdanderson.org

Writing assistance was provided by Cory Pfeiffenberger, PhD (Complete Healthcare Communications, Inc.), whose work was funded by Incyte Corporation.

Subjects:

Research Funding:

J-JK has received honoraria and research funding from Novartis Pharmaceuticals and has served on advisory boards for Novartis Pharmaceuticals.

EFW has received research funding from Gilead Sciences Inc., Incyte Corporation, Pfizer, and Sanofi, and has served on advisory boards for Incyte Corporation.

MT has received research funding from ARIAD, Bristol-Myers Squibb, Sanofi, Incyte Corporation, and Pfizer.

SV has received research funding from Astrazeneca, Bristol Myers Squibb, Celgene, Cell Therapeutics Inc., Galena BioPharma, Geron, Gilead Sciences Inc., Incyte Corporation, Infinity Pharmaceuticals, Lilly Oncology, NS Pharma, Pfizer, Promedior, Roche, and Seattle Genetics.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology
  • erythrocytosis
  • Janus kinase 1
  • Janus kinase 2
  • myeloproliferative neoplasm
  • polycythemia vera
  • ruxolitinib
  • splenomegaly
  • thrombocytosis
  • CHRONIC MYELOPROLIFERATIVE NEOPLASMS
  • QUALITY-OF-LIFE
  • PEGYLATED INTERFERON ALPHA-2A
  • TYROSINE KINASE JAK2
  • ESSENTIAL THROMBOCYTHEMIA
  • PRECLINICAL CHARACTERIZATION
  • INCB018424 PHOSPHATE
  • SIGNAL-TRANSDUCTION
  • HEALTHY-VOLUNTEERS
  • RANDOMIZED-TRIAL

Ruxolitinib for the treatment of patients with polycythemia vera

Tools:

Journal Title:

Expert Review of Hematology

Volume:

Volume 8, Number 4

Publisher:

, Pages 391-401

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Polycythemia vera (PV) is a hematopoietic proliferative disorder associated with Janus-associated kinase/signal transducer and activator of transcription pathway dysregulation resulting in erythrocytosis and, possibly, leukocytosis and thrombocytosis. Patients diagnosed with PV experience a broad range of symptoms associated with a reduced quality of life, often develop splenomegaly, and have an increased risk of death compared with age-matched subjects without PV. Current treatment options, notably hydroxyurea, help with disease management; however, insufficient efficacy or progressive resistance occurs in some patients, highlighting the need for new treatment options. Ruxolitinib is an oral JAK1/JAK2 inhibitor that has been evaluated in Phase II and III clinical trials in patients with PV, who are intolerant of or resistant to hydroxyurea. In this setting, ruxolitinib treatment has demonstrated normalization of blood cell counts, reduction in splenomegaly and improvements in PV-related symptom burden.

Copyright information:

© Informa UK, Ltd.

Export to EndNote